Oxford Biomedica sees FY23 revenue GBP 90M

In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately GBP 90 million. Operating EBITDA loss for the second half of 2023 is on track to be approximately GBP 10 million better than the first half, as previously guided. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “OXB is continuing to successfully deliver its pure-play CDMO strategy. Our expansion into the European Union through the acquisition of ABL Europe strengthens our vector-agnostic service offering and strongly demonstrates our commitment to global client service and excellence. With these developments and our growing order book, we are confident about accelerating our financial performance and fulfilling our updated medium-term guidance.”